Department of Emergency Surgery, Jining No.1 People's Hospital, Jining 272000, Shandong, China.
Department of Medical Abministration, Jining No.1 People's Hospital, Jining 272000, Shandong, China.
Biomed Pharmacother. 2018 Jun;102:169-174. doi: 10.1016/j.biopha.2018.02.081. Epub 2018 Mar 22.
LncRNA CBR3-AS1 has been suggested to promote malignancy in several types of human cancers, but the clinical significance and biological function of lncRNA CBR3-AS1 in osteosarcoma is still unknown. The purpose of our study is to explore the clinical significance of lncRNA CBR3-AS1 in osteosarcoma patients and the biological function in osteosarcoma cells. In our results, we found lncRNA CBR3-AS1 was highly-expressed in osteosarcoma tissues and cell lines, and associated with Enneking stage, distant metastasis and histological grade. Survival analysis indicated that the high-expression of lncRNA CBR3-AS1 was an independent poor prognostic factor for osteosarcoma patients. Loss-of-function studies showed knockdown of lncRNA CBR3-AS1 suppressed osteosarcoma cells proliferation, migration and invasion, and promotes cells apoptosis, but had no effect on cell-cycle distribution. There was no association between lncRNA CBR3-AS1 and CBR3 expression in osteosarcoma tissues, and knockdown of lncRNA CBR3-AS1 had no effect on CBR3 mRNA and protein expression osteosarcoma cells. In conclusion, lncRNA CBR3-AS1 serves an oncogenic role to regulate osteosarcoma cells proliferation, migration, invasion and apoptosis, and is an independent poor prognostic factor for osteosarcoma patients.
LncRNA CBR3-AS1 被认为在几种人类癌症中促进恶性肿瘤的发生,但 lncRNA CBR3-AS1 在骨肉瘤中的临床意义和生物学功能仍不清楚。我们的研究目的是探讨 lncRNA CBR3-AS1 在骨肉瘤患者中的临床意义及其在骨肉瘤细胞中的生物学功能。在我们的研究结果中,我们发现 lncRNA CBR3-AS1 在骨肉瘤组织和细胞系中高表达,与 Enneking 分期、远处转移和组织学分级相关。生存分析表明,lncRNA CBR3-AS1 的高表达是骨肉瘤患者独立的不良预后因素。功能丧失研究表明,lncRNA CBR3-AS1 的敲低抑制了骨肉瘤细胞的增殖、迁移和侵袭,并促进了细胞凋亡,但对细胞周期分布没有影响。lncRNA CBR3-AS1 与骨肉瘤组织中的 CBR3 表达之间没有关联,lncRNA CBR3-AS1 的敲低对骨肉瘤细胞中的 CBR3 mRNA 和蛋白表达没有影响。总之,lncRNA CBR3-AS1 作为一种癌基因,通过调节骨肉瘤细胞的增殖、迁移、侵袭和凋亡,发挥作用,并成为骨肉瘤患者独立的不良预后因素。